Loading...
Loading...
OvaScienceSM
OVAS today announced that the Company does not expect to
meet the 2015 goal of 1,000 AUGMENTSM treatment cycles. The
AUGMENT treatment patient experience has been positive and OvaScience
has built strong technical operations, quality and manufacturing;
however, the Company is continuing to enhance its commercial operations
and infrastructure to optimize for commercial success. In addition,
evolving market dynamics in the fertility space, including recent merger
and acquisition activities at the key commercial IVF clinics where the
AUGMENT treatment is offered, have hindered the Company's ability to
drive major volume that was anticipated in the fourth quarter.
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in